GT Biopharma, Inc.

GTBP Healthcare Biotechnology

In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.

7.03 0.33 −4.48%
Market cap
$15.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−5138.41
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(1,205.42%) (1,674.31%) (1,122.83%) 102.03%
ROA
(554.30%) (558.42%) (585.46%) (176.27%)
ROIC
(1,746.37%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(1,023.60%) (595.28%) (488.68%) (318.86%)
Free Cash Flow per Share
(72.09) (58.57) (10.88) (9.29)
Free Cash Flow
(11.36) (12.91) (13.18) (14.43)
Other line items

Show all line items

Columns are period end dates